VibioSphen is a French biotechnology company in infectious diseases (ID) specialized in developing solutions, models and new immunomodulation treatments add-on to antibiotics, to fight nosocomial infections.
It offers of a wide range of bacterial, viral and fungal in vivo models using clinical pathogen strains to improve predictivity: pneumonia, septicemia, Urinary Tract Infection (UTI) (acute E coli pyelonephritis and recurrent UTI), thigh, gastrointestinal infections and pulmonary co-infection models (CRO activity). Our expertise in microbiology is focused on key resistant pathogens: P. aeruginosa, S. pneumonia, S. aureus, K. pneumonia, E. coli, C. difficile,M. tuberculosis for bacteria; C. albicans and A. fumigatus for fungi and flu virus : H1N1…Various end-points points (clinical symptoms, pathogen load, cytokines, immune cell quantification, histopathology...) and analysis (PK,pharmacokinetics; PK/PD, pharmacodynamics; pathogen genotyping; MIC, Minimum Inhibitory Concentrations) are available to characterize both drugs and pathology.
VibioSphen research and innovation (R&I) activity targets development of novel immunotherapies complementary to antibiotics against severe HAP/VAP and resistant pathogens. Immunomodulator compounds, at advanced-stage candidates, are undergoing proof of concept in various bacterial pneumonia models in rodents
Moreover, the team has a strong experience in ID and expertise in pharmaceutical drug development (small molecules or biologics) and is involved in several partnerships and academic collaborations.
VibioSphen is looking for technical and research collaborations in the fields of ID, host-pathogen interaction and immunomodulation. In the the frame of H2020 partnerships, VibioSphen propose:
• to provide consortium with translational preclinical infectious models and expertise to develop new antimicrobial strategies.
• to join or build MSCA (Marie Slodowska Curie Actions) consortium to train and deliver expert scientists (PhD or PostDoc) in infectious diseases, immunomodulation therapy, new antibiotics and host-pathogen interactions.